Merck: Q3 Earnings Snapshot
And the good results of the company’s flagship oncology drug is not the only purpose that MRK stock is up 25% for the year. Inflation remains close to 40-year highs and yet employment also remains at historically higher levels. Adjusted earnings of $1.85 for the third quarter included a 22-cent charge related to collaboration and licensing agreements with Moderna Inc. and other biotech corporations. As we described earlier, the global pandemic has impacted pharmaceutical companies in a adverse way over…